Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials [Breast Cancer]
Conclusion Premenopausal women with hormone receptor–positive, HER2-negative disease and high recurrence risk, as defined by clinicopathologic characteristics, may experience improvement of 10% to 15% in 5-year BCFI with exemestane plus OFS versus tamoxifen alone. An improvement of at least 5% may be achieved for women at intermediate risk, and improvement is minimal for those at lowest risk. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Regan, Francis, Pagani, Fleming, Walley, Viale, Colleoni, Lang, Gomez, Tondini, Pinotti, Price, Coates, Goldhirsch, Gelber Tags: Hormonal Therapy Breast Cancer Source Type: research

Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation [Hematologic Malignancy]
Purpose We investigated the effect of Epstein-Barr virus (EBV) serostatus on the overall outcome of allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Patients and Methods The study included 11,364 patients who underwent allogeneic peripheral-blood or bone marrow transplantation for acute leukemia between 1997 and 2012. We analyzed the impact of donor and recipient EBV serologic status on overall survival, relapse-free survival, relapse incidence, nonrelapse mortality, and incidence of graft-versus-host disease (GVHD) after allo-HSCT. Results Patients receiving grafts from EBV-seropositive donors had the sam...
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Styczynski, Tridello, Gil, Ljungman, Hoek, Iacobelli, Ward, Cordonnier, Einsele, Socie, Milpied, Veelken, Chevallier, Yakoub-Agha, Maertens, Blaise, Cornelissen, Michallet, Daguindau, Petersen, Passweg, Greinix, Duarte, Kroger, Dreger, Mohty, Nagler, Cesa Tags: Combined Therapy, Biology & Immunology Hematologic Malignancy Source Type: research

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency [Rapid Communication]
Purpose Recurrent glioblastoma multiforme (GBM) is incurable with current therapies. Biallelic mismatch repair deficiency (bMMRD) is a highly penetrant childhood cancer syndrome often resulting in GBM characterized by a high mutational burden. Evidence suggests that high mutation and neoantigen loads are associated with response to immune checkpoint inhibition. Patients and Methods We performed exome sequencing and neoantigen prediction on 37 bMMRD cancers and compared them with childhood and adult brain neoplasms. Neoantigen prediction bMMRD GBM was compared with responsive adult cancers from multiple tissues. Two siblin...
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Bouffet, Larouche, Campbell, Merico, de Borja, Aronson, Durno, Krueger, Cabric, Ramaswamy, Zhukova, Mason, Farah, Afzal, Yalon, Rechavi, Magimairajan, Walsh, Constantini, Dvir, Elhasid, Reddy, Osborn, Sullivan, Hansford, Dodgshun, Klauber-Demore, Peterson Tags: Brain Tumors, Translational Oncology, Hereditary Cancers & Genetic Predisposition, CNS Tumors, Rapid Communications Source Type: research

Still Refining Adjuvant Endocrine Therapy in Premenopausal Women: Not Too Much, Not Too Little [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Wolff, Rugo Tags: Chemotherapy, Hormonal Therapy EDITORIALS Source Type: research

Epstein-Barr Virus and B Cells in the Pathogenesis of Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem-Cell Transplantation [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Rezvani, Champlin Tags: Leukemia, Biology & Immunology, Biology & Immunology EDITORIALS Source Type: research

Top 50 Most-Cited Journal of Clinical Oncology Articles From 2013 [SPECIAL ARTICLE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Tags: SPECIAL ARTICLE Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

Erratum [erratum]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Tags: ERRATUM Source Type: research

The First Step to Integrating Adapted Common Terminology Criteria for Adverse Events for Children [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: de Rojas, Bautista, Madero, Moreno Tags: CORRESPONDENCE Source Type: research

Reply to D.W. Felsher et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Shulman, Wagner, Torode Tags: CORRESPONDENCE Source Type: research

Affordable Cancer Medications Are Within Reach but We Need a Different Approach [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Felsher, Lowe Tags: CORRESPONDENCE Source Type: research

Reply to T. Finazzi and H. Kim et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Knisely Tags: CORRESPONDENCE Source Type: research

Reply to H. Kim et al and T. Finazzi [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Roa, Ghosh, Zhu, Baker Tags: CORRESPONDENCE Source Type: research

One Week of Radiotherapy for Glioblastoma: A Noninferiority Trial? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Finazzi Tags: CORRESPONDENCE Source Type: research

Too Little, Too Soon: Short-Course Radiotherapy in Elderly Patients With Glioblastoma [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Kim, Leiby, Shi Tags: CORRESPONDENCE Source Type: research

Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement [ASCO SPECIAL ARTICLE]
Purpose To endorse Cancer Care Ontario’s guideline on Active Surveillance for the Management of Localized Prostate Cancer. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines developed by other professional organizations. Methods The Active Surveillance for the Management of Localized Prostate Cancer guideline was reviewed for developmental rigor by methodologists. The ASCO Endorsement Panel then reviewed the content and the recommendations. Results The ASCO Endorsement Panel determined that the recommendations from the Active Surveillance f...
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Chen, Rumble, Loblaw, Finelli, Ehdaie, Cooperberg, Morgan, Tyldesley, Haluschak, Tan, Justman, Jain Tags: ASCO Guidelines, Non-ASCO Guidelines, Epidemiology & Prevention, Diagnosis & Staging ASCO SPECIAL ARTICLE Source Type: research

Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome [REVIEW ARTICLE]
Von Hippel-Lindau disease (VHL) is one of the most common inherited neoplasia syndromes and is characterized by highly vascular tumors of the eyes, brain, and spine, as well as benign and malignant tumors and/or cysts of the kidneys, adrenal medullae and sympathetic paraganglia, endolymphatic sac, epididymis, and broad ligament. Since the discovery of the VHL gene in 1993, more than 900 families with VHL have been identified and examined. Genetic testing for VHL is widely available and will detect a disease-causing mutation in rate 95% to 100% of individuals who have a clinical diagnosis of VHL, making it the standard of c...
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Nielsen, Rhodes, Blanco, Chung, Eng, Maher, Richard, Giles Tags: REVIEW ARTICLE Source Type: research

Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations [Urologic Oncology]
Purpose Somatic mutations and copy number variation in the ERBB family are frequent in urothelial carcinoma (UC) and may represent viable therapeutic targets. We studied whether afatinib (an oral, irreversible inhibitor of the ErbB family) has activity in UC and if specific ERBB molecular alterations are associated with clinical response. Patients and Methods In this phase II trial, patients with metastatic platinum-refractory UC received afatinib 40 mg/day continuously until progression or intolerance. The primary end point was 3-month progression-free survival (PFS3). Prespecified tumor analysis for alterations in EGFR,...
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Choudhury, Campanile, Antic, Yap, Fitzpatrick, Wade, Karrison, Stadler, Nakamura, ODonnell Tags: Clinical Trials, Translational Oncology, Genitourinary, Cancer Biomarkers Urologic Oncology Source Type: research

Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer [Gastrointestinal Cancer]
Purpose To develop and validate a radiomics nomogram for preoperative prediction of lymph node (LN) metastasis in patients with colorectal cancer (CRC). Patients and Methods The prediction model was developed in a primary cohort that consisted of 326 patients with clinicopathologically confirmed CRC, and data was gathered from January 2007 to April 2010. Radiomic features were extracted from portal venous–phase computed tomography (CT) of CRC. Lasso regression model was used for data dimension reduction, feature selection, and radiomics signature building. Multivariable logistic regression analysis was used to devel...
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Huang, Liang, He, Tian, Liang, Chen, Ma, Liu Tags: Risk factors, Diagnosis & Staging, Translational Oncology, CT, Gastrointestinal, Cancer Biomarkers Gastrointestinal Cancer Source Type: research

Racial/Ethnic Disparities in Survival Among Patients With Young-Onset Colorectal Cancer [Gastrointestinal Cancer]
Purpose Racial disparities in colorectal cancer (CRC) persist, despite overall reductions in morbidity and mortality. In addition, incidence is rising among individuals younger than 50 years of age. We compared the survival of young-onset CRC among non-Hispanic black (NHB), non-Hispanic white (NHW), and Hispanic individuals. Patients and Methods Using the National Cancer Institute’s Surveillance, Epidemiology, and End Results program data, we identified individuals between the ages of 20 and 49 years, diagnosed with CRC between 2000 and 2009. Survival rates and Cox proportional hazards models were used to compare st...
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Holowatyj, Ruterbusch, Rozek, Cote, Stoffel Tags: Population and observational studies (SEER, WHI observational, etc.), Epidemiology Gastrointestinal Cancer Source Type: research

Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels [Gastrointestinal Cancer]
Purpose Tumor screening for Lynch syndrome is recommended in all or most patients with colorectal cancer (CRC). In metastatic CRC, sequencing of RAS/BRAF is necessary to guide clinical management. We hypothesized that a next-generation sequencing (NGS) panel that identifies RAS/BRAF and other actionable mutations could also reliably identify tumors with DNA mismatch repair protein deficiency (MMR-D) on the basis of increased mutational load. Methods We identified all CRCs that underwent genomic mutation profiling with a custom NGS assay (MSK-IMPACT) between March 2014 and July 2015. Tumor mutational load, with exclusion o...
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Stadler, Battaglin, Middha, Hechtman, Tran, Cercek, Yaeger, Segal, Varghese, Reidy-Lagunes, Kemeny, Salo-Mullen, Ashraf, Weiser, Garcia-Aguilar, Robson, Offit, Arcila, Berger, Shia, Solit, Saltz Tags: ASCO Guidelines, Diagnosis & Staging, Translational Oncology, Gastrointestinal, Gene Expression and Profiling, Oncogenes Gastrointestinal Cancer Source Type: research

Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia [Hematologic Malignancy]
Purpose Acute pancreatitis is one of the common causes of asparaginase intolerance. The mechanism is unknown, and genetic predisposition to asparaginase-induced pancreatitis has not been previously identified. Methods To determine clinical risk factors for asparaginase-induced pancreatitis, we studied a cohort of 5,185 children and young adults with acute lymphoblastic leukemia, including 117 (2.3%) who were diagnosed with at least one episode of acute pancreatitis during therapy. A genome-wide association study was performed in the cohort and in an independent case-control group of 213 patients to identify genetic risk f...
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Liu, Yang, Devidas, Cheng, Pei, Smith, Carroll, Raetz, Bowman, Larsen, Maloney, Martin, Mattano, Winick, Mardis, Fulton, Bhojwani, Howard, Jeha, Pui, Hunger, Evans, Loh, Relling Tags: Acute Lymphoblastic Leukemia Hematologic Malignancy Source Type: research

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myelome [Hematologic Malignancy]
Purpose Primary plasma cell leukemia (pPCL) is a rare and aggressive malignancy with a poor prognosis. With conventional chemotherapy, patients typically die within 1 year. In all but one of the retrospective studies reported to date, bortezomib and lenalidomide seem to improve survival. We conducted a prospective phase II trial in patients with pPCL to assess the efficacy of an alternate regimen that combines standard chemotherapy, a proteasome inhibitor, and high-dose melphalan and autologous stem cell transplantation (HDM/ASCT) followed by either allogeneic transplantation or bortezomib/lenalidomide maintenance. Patien...
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Royer, Minvielle, Diouf, Roussel, Karlin, Hulin, Arnulf, Macro, Cailleres, Brion, Brechignac, Belhadj, Chretien, Wetterwald, Chaleteix, Tiab, Leleu, Frenzel, Garderet, Choquet, Fuzibet, Dauriac, Forneker, Benboubker, Facon, Moreau, Avet-Loiseau, Marolleau Tags: Myeloma, Diagnosis & Staging, Chemotherapy Hematologic Malignancy Source Type: research

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3 [Breast Cancer]
Conclusion This analysis, although exploratory, suggests that patients with human epidermal growth factor receptor 2–positive advanced breast cancer having tumors with PIK3CA mutations, PTEN loss, or hyperactive PI3K pathway could derive PFS benefit from everolimus. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Andre, Hurvitz, Fasolo, Tseng, Jerusalem, Wilks, ORegan, Isaacs, Toi, Burris, He, Robinson, Riester, Taran, Chen, Slamon Tags: Cancer Biomarkers Breast Cancer Source Type: research

Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer [Breast Cancer]
Purpose The aim of this study was to evaluate contemporary rates of local recurrence (LR) and regional recurrence (RR) in young patients with breast cancer in relation to tumor biology as expressed by biomarker subtypes. Patients and Methods Women
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Aalders, Postma, Strobbe, van der Heiden-van der Loo, Sonke, Boersma, van Diest, Siesling, van Dalen Tags: Epidemiology, Surgery, Radiation, Chemotherapy, Combined Modality, Hormonal Therapy, Translational Oncology, Risk factors, Radiation Oncology, Surgical Oncology Breast Cancer Source Type: research

Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial [Rapid Communication]
Purpose Enzalutamide, a potent oral androgen receptor inhibitor, improves survival in men with metastatic castration-resistant prostate cancer (CRPC) before and after chemotherapy. Bicalutamide, a nonsteroidal antiandrogen, is widely used to treat men with nonmetastatic or metastatic CRPC. The efficacy and safety of these drugs were compared in this randomized, double-blind, phase II study of men with CRPC. Patients and Methods A total of 396 men with nonmetastatic (n = 139) or metastatic (n = 257) CRPC were randomly assigned to enzalutamide 160 mg per day (n = 198) or bicalutamide 50 mg per day (n = 198). Androgen depriv...
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Penson, Armstrong, Concepcion, Agarwal, Olsson, Karsh, Dunshee, Wang, Wu, Krivoshik, Phung, Higano Tags: Systemic Therapy, Systemic Therapy, Rapid Communications Source Type: research

Mammographic Density as a Biosensor of Tamoxifen Effectiveness in Adjuvant Endocrine Treatment of Breast Cancer: Opportunities and Implications [COMMENTS AND CONTROVERSIES]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Mullooly, Pfeiffer, Nyante, Heckman-Stoddard, Perloff, Jatoi, Brinton, Aiello Bowles, Hoover, Glass, Berrington de Gonzalez, Sherman, Gierach Tags: Epidemiology, Hormonal Therapy, Breast Imaging, Breast Cancer COMMENTS AND CONTROVERSIES Source Type: research

Targeted Therapy for Metastatic Urothelial Cancer: A Work in Progress [ONCOLOGY GRAND ROUNDS]
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 64-year-old man presented to the clinic to discuss treatment options for progressive metastatic urothel...
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Plimack, Geynisman Tags: Oncology Grand Rounds Source Type: research

Mismatch Repair Deficiency in Colorectal Cancers: Is Somatic Genomic Testing the Grab-Bag for All Answers? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Ngeow, Eng Tags: Translational Oncology, Hereditary Cancers & Genetic Predisposition EDITORIALS Source Type: research

Progress in the Treatment of Primary Plasma Cell Leukemia [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Musto Tags: EDITORIALS Source Type: research

A Rosier Picture for Young Women With Breast Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Warner Tags: EDITORIALS Source Type: research

Striving Toward a Cure for Prostate Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Stein, Jang Tags: EDITORIALS Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

Reply to N.F. Saba and S.J. Wong [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Harrington, Bourhis Tags: CORRESPONDENCE Source Type: research

Dual Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Inhibition in Squamous Cell Carcinoma of the Head and Neck; Is the Jury Still Out? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Saba, Wong Tags: CORRESPONDENCE Source Type: research

Reply to S. Kilickap et al, Y. Karakas et al, and I.A. Voutsadakis [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Morden, Eeles, Bliss Tags: CORRESPONDENCE Source Type: research

On Adjuvant Hormone Therapy in Epithelial Ovarian Cancer [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Voutsadakis Tags: CORRESPONDENCE Source Type: research

Analysis of the Adjuvant Hormone Therapy Randomized Trial [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Karakas, Akin, Dizdar, Aksoy Tags: CORRESPONDENCE Source Type: research

Does Adjuvant Hormone Therapy Improve Survival in Epithelial Ovarian Cancer? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Kilickap, Tural Tags: CORRESPONDENCE Source Type: research

Reply to O.O. Eren et al and S. Mikhail [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Shah Tags: CORRESPONDENCE Source Type: research

"Does the Punishment Fit the Crime?" [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Mikhail Tags: CORRESPONDENCE Source Type: research

Is It Time for Maintenance Chemotherapy for Advanced Gastric Adenocarcinoma? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Eren, Sonmez, Oyan Tags: CORRESPONDENCE Source Type: research

Biomarker Tests for Molecularly Targeted Therapies: Laying the Foundation and Fulfilling the Dream [SPECIAL ARTICLE]
This article presents an overview of the committee’s study and resulting recommendations, which cover establishment of clinical utility, regulatory oversight, coverage and reimbursement, health system data integration, as well as education and access. The committee’s recommendations presented and discussed here are fundamentally grounded in the understanding that, when properly validated and appropriately implemented, these assays and corresponding therapies hold considerable promise to enhance the quality of patient care and improve meaningful clinical outcomes. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Lyman, Moses Tags: Non-ASCO Guidelines, Cancer Biomarkers, Other SPECIAL ARTICLE Source Type: research

Strategies for Empiric Management of Pediatric Fever and Neutropenia in Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: A Systematic Review of Randomized Trials [REVIEW ARTICLE]
Purpose To describe treatment failure and mortality rates with different antibiotic regimens and different management strategies for empirical treatment of fever and neutropenia (FN) in pediatric patients with cancer and hematopoietic stem-cell transplantation (HSCT) recipients. Methods We conducted a systematic review and performed searches of MEDLINE, Embase, PubMed, and Cochrane Central Register of Controlled Trials. Studies were included if pediatric patients had cancer or were HSCT recipients and the intervention was related to the management of FN. Strategies synthesized were monotherapy versus aminoglycoside-contai...
Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Robinson, Lehrnbecher, Phillips, Dupuis, Sung Tags: Growth Factors, Supportive Care, Febrile Neutropenia, Supportive Care REVIEW ARTICLE Source Type: research

Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone [Gastrointestinal Cancer]
Conclusion There was no apparent difference between the treatment arms. These results challenge the use of doxorubicin-eluting beads for chemoembolization of HCC. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Brown, Do, Gonen, Covey, Getrajdman, Sofocleous, Jarnagin, DAngelica, Allen, Erinjeri, Brody, ONeill, Johnson, Garcia, Beattie, Zhao, Solomon, Schwartz, DeMatteo, Abou-Alfa Tags: Clinical Trials, Chemotherapy, Combined Modality, Interventional Radiology Gastrointestinal Cancer Source Type: research

European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis [Hematologic Malignancy]
Purpose Immunoglobulin M (IgM)–related light chain (AL) amyloidosis, which accounts for 6% to 10% of all AL amyloidosis cases, is a rare and poorly studied clinical entity. Its natural history and management is not clearly defined. Prognostic and response criteria for AL amyloidosis in general have not been validated in this population. Patients and Methods We retrospectively gathered data for 250 patients diagnosed with IgM AL amyloidosis from three European amyloidosis centers. Clinical features, hematologic response, and overall survival (OS) were analyzed. The current staging and response criteria in non-IgM AL ...
Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Sachchithanantham, Roussel, Palladini, Klersy, Mahmood, Venner, Gibbs, Gillmore, Lachmann, Hawkins, Jaccard, Merlini, Wechalekar Tags: Diagnosis & Staging, Diagnosis & Staging Hematologic Malignancy Source Type: research

Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score >= 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial [Hematologic Malignancy]
Conclusion ABVD8 and BEACOPP4+4 resulted in similar EFS and OS in patients with high-risk advanced-stage HL. Because BEACOPP4+4 did not demonstrate a favorable effectiveness or toxicity ratio compared with ABVD8, treatment burden, immediate and late toxicities, and associated costs must be considered before selecting one of these regimens on which to build future treatment strategies. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Carde, Karrasch, Fortpied, Brice, Khaled, Casasnovas, Caillot, Gaillard, Bologna, Ferme, Lugtenburg, Morschhauser, Aurer, Coiffier, Meyer, Seftel, Wolf, Glimelius, Sureda, Mounier Tags: Chemotherapy Hematologic Malignancy Source Type: research

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816 [Hematologic Malignancy]
Conclusion Response-adapted therapy based on interim PET imaging after two cycles of ABVD seems promising with a 2-year PFS of 64% for PET2-positive patients, which is much higher than the expected 2-year PFS of 15% to 30%. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Press, Li, Schoder, Straus, Moskowitz, LeBlanc, Rimsza, Bartlett, Evens, Mittra, LaCasce, Sweetenham, Barr, Fanale, Knopp, Noy, Hsi, Cook, Lechowicz, Gascoyne, Leonard, Kahl, Cheson, Fisher, Friedberg Tags: Clinical Trials, Risk factors, Diagnosis & Staging, Chemotherapy, Nuclear Medicine Hematologic Malignancy Source Type: research

Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers [Cancer Prevention and Control]
Conclusion Surveillance of CDNK2A mutation carriers is relatively successful, detecting most PDACs at a resectable stage. The benefit of surveillance in families with FPC is less evident. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Vasen, Ibrahim, Ponce, Slater, Matthai, Carrato, Earl, Robbers, van Mil, Potjer, Bonsing, de Vos tot Nederveen Cappel, Bergman, Wasser, Morreau, Kloppel, Schicker, Steinkamp, Figiel, Esposito, Mocci, Vazquez-Sequeiros, Sanjuanbenito, Munoz-Beltran, Montan Tags: Prognostic Studies, Population and observational studies (SEER, WHI observational, etc.) Cancer Prevention and Control Source Type: research

Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer [Breast Cancer]
Conclusion Approxemately one half of patients 65 years of age and older with stage I to III breast cancer do not receive trastuzumab-based therapy, which includes many with locally advanced disease. Significant racial disparities exist in the receipt of this highly effective therapy. Further research that identifies barriers to use and increases uptake of trastuzumab could potentially improve recurrence and survival outcomes in this population, particularly among minority women. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Reeder-Hayes, Peacock Hinton, Meng, Carey, Dusetzina Tags: Epidemiology, Chemotherapy, Population and observational studies (SEER, WHI observational, etc.) Breast Cancer Source Type: research